+1 (304) 470-2225

Multiple System Atrophy’s Competitive Landscape 2020

Multiple system atrophy (MSA) is a rare, degenerative neurological disorder affecting your body’s involuntary (autonomic) functions, including blood pressure, breathing, bladder function and motor control. MSA shares many Parkinson’s disease-like symptoms, such as slow movement, rigid muscles and poor balance.

2020 Events in Multiple system atrophy


Two most recent drug update which has caught the eyes in the Multiple System Atrophy (MSA) Competitive Landscape

Verdiperstat by Biohaven Pharmaceutical

Verdiperstat by Biohaven Pharmaceutical is a unique orally administered MPO inhibitor. The MPO enzyme acts as a key driver of oxidative stress and inflammation that underlies neurodegeneration and is abundant in activated microglial cells found in the brains of patients with MSA. Phase 3 completion of enrolment announced July 21, 2020. Top-line data anticipated by the end of 2021.

ATH434 by Alterity Therapeutics

ATH434, previously known as PBT434 by Alterity Therapeutics is company’s lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder. ATH434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration and is has shown to reduce abnormal accumulation of α-synuclein and tau proteins by restoring normal iron balance in animal models of Multiple System Atrophy in the brain.

Thus, it differs from other candidates with its unique mechanism under trials and is believed to has excellent potential to treat various forms of atypical Parkinsonism by researchers.

How ATH434 edges over other drugs with FDA’s support for Alterity

The FDA has encouraged Alterity to utilize data from a natural history study, planned with clinical and neuroimaging experts at Vanderbilt University Medical Center in the US by Alterity.
The FDA and Alterity will also be working together to develop an endpoint that is best suited for the MSA patients to be studied.

It is the first Drug to have reached Phase 2 straight after Pre approved IND approval.

Irfan Qureshi, MD, vice president of neurology at Biohaven, told NeurologyLive, said

Biohaven sees the potential for verdiperstat to be the first disease-modifying treatment for MSA. No disease-modifying treatments currently exist for MSA; only symptomatic and palliative therapies are available,”

The ongoing trials on Multiple System Atrophy (MSA)

MSA Competitive SpaceThe figure provides a clear view regarding the current scenario in Multiple System Atrophy market.

Out of nine therapies, six of them are in Phase 1 and Phase 2,  two in phase 3 and one in Phase 2 (planned). We, Mellalta Meets believes that the coming years will be more dramatic in MSA space, as many companies have to meet the desired treatment efficacy for their products.


List of Trials in Multiple System Atrophy (MSA)

NCT Number






Biohaven Pharmaceuticals, Inc.


Multiple System Atrophy

Phase 3


GE Healthcare|PPD

DaTSCANâ„¢ Ioflupane (123I) Injection

Parkinsonian Syndrome|Parkinson Disease (PD)|Multiple System Atrophy (MSA)|Progressive Supranuclear Palsy (PSP)

Phase 3


Zambon SpA

Safinamide Methanesulfonate

Multiple System Atrophy

Phase 2




Progressive Supranuclear Palsy|Multiple System Atrophy

Phase 2


Loma Linda University|H. Lundbeck A/S


Parkinson Disease|Multiple System Atrophy|Progressive Supranuclear Palsy

Phase 2




Multiple System Atrophy

Phase 1


Corestem, Inc.


Multiple System Atrophy

Phase 1


MODAG GmbH|Quotient Sciences|Aptuit (Verona) Srl, an Evotec Company


Healthy Volunteers

Phase 1


Alterity Therapeutics


Multiple System Atrophy

Phase 2 Planned

Why Multiple System Atrophy is a major concern and a big area of focus?

Multiple System Atrophy member of the ‘parkinsonian syndromes, previously known as Shy-Drager Syndrome, is a rare and fatal disorder with less than 15,000 Americans diagnosed at any given time.

And as per our findings, Mellalta Meets strongly believe that with no approved treatments for MSA and no regulatory precedent regarding accepted efficacy endpoints, we are not very far away from getting a treatment for Multiple System Atrophy.

Click here for more information on the direct and Indirect competitors for Elacestrant in ER+/HER2- mBC. If you wish to learn more on how Mellalta can be of assistance, Click here.

You might be interested in …

Leave a Reply

Get In Touch

Let's keep the conversation going